Chordoma Global Clinical Trials Review, H1, 2017

2017-06-30
Price :
Published : Jun-2017
No. of Pages : 54

Chordoma Global Clinical Trials Review, H1, 2017

Summary

GlobalData’s clinical trial report, “Chordoma Global Clinical Trials Review, H1, 2017” provides an overview of Chordoma clinical trials scenario. This report provides top line data relating to the clinical trials on Chordoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users Covid-19 Impact – Forecast to 2025

 “The US therapeutic plasma exchange market is projected to grow at a CAGR of 6.3%.” The US therapeutic plasma exchange market is projected to reach USD 243 million by 2025 from USD 178 million in 2020, at a CAGR of 6.3% during the forecast period. Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period. “The consumables segment to grow at the highest rate during the forecast period.” On the basis of products, the US therapeutic plasma exchange market has been s......
$4950

Pharmaceutical Trade and Supply Chain Survey, Q3 2020 – Coronavirus Disease 2019 (COVID-19) Impact

Pharmaceutical Trade and Supply Chain Survey, Q3 2020 - Coronavirus Disease 2019 (COVID-19) Impact Summary This report provides an update on the assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing. Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe. Scope - Report provides in-house analyst expertise on the results of a 5 minute survey of 75 GlobalData Pharma clients and prospects, which was fielded from July 7, 2020 to July 30, 2020. Reasons to Buy Objectives included - - Benchmark companies' primary concerns - Determine the impact of......
$1495

Coronavirus Disease 2019 (COVID-19) Case Study – A Look at Increased Cybersecurity Risk Across the Healthcare Industry

Coronavirus Disease 2019 (COVID-19) Case Study - A Look at Increased Cybersecurity Risk Across the Healthcare Industry Summary The COVID-19 pandemic has increased cyber risk significantly, with certain situations being exploited by malicious actors during the crisis. This includes a rush to utilize remote working with little time to plan or train employees, a high demand for personal protective equipment (PPE), lockdown measures, reduced mobility, and increased fear and anxiety among the public. This case study contains a review of the rise in cyber attacks on the healthcare industry seen during the COVID-19 pandemic, with examples of attacks on biopharmaceutical and research companies, hospitals, payers, and other healthcare providers. Key Highlights - Hospitals and healthcare provide......
$595

Amyotrophic Lateral Sclerosis (ALS) – Opportunity Analysis and Forecasts to 2029

Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2029 Summary Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS). ALS current treatment includes only two disease-modifying drugs: Sanofi's Rilutek (riluzole) and Mitsubishi Tanabe's Radicava/Radicut (edaravone). Two reformulations of riluzole were approved recently: ITF Pharma's Tiglutik (riluzole oral suspension) in 2018 and Aq......
$10995

Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2029

Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2029 Summary Amyotrophic lateral sclerosis (ALS) is a group of rare but fatal neurodegenerative diseases that primarily involve the nerve cells (neurons) in the brain and spinal cord responsible for controlling voluntary muscle movement like chewing, walking, and talking (National Institute of Neurological Disorders and Stroke, 2020). ALS is often called Lou Gehrig's disease, after the baseball player who was diagnosed with the disease in 1939 (Mayo Clinic, 2019). Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear. Currently, there is no cure for ALS and no effective treatment to stop, or reverse, the progression of the disease (National Institute of Neurologica......
$3995

Gastric and Gastroesophageal Junction Adenocarcinoma – Epidemiology Forecast to 2029

Gastric and Gastroesophageal Junction Adenocarcinoma - Epidemiology Forecast to 2029 Summary Gastric cancer, also known as stomach cancer, occurs when cancer cells form in the lining of the stomach. Approximately 90% to 95% of gastric cancer cases are considered to be an adenocarcinoma, a cancer that develops in the mucosa—the innermost layer of the stomach. Gastric cancer usually develops slowly and rarely shows any signs or symptoms in the early stages. The majority of gastric cancer cases are diagnosed at an advanced stage. Symptoms of gastric cancer can include poor appetite, weight loss, abdominal pain, nausea, blood in the stool, and vomiting. GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the obs......
$3995

Crohn’s Disease – Epidemiology Forecast to 2029

Crohn's Disease - Epidemiology Forecast to 2029 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. It most commonly affects the end of the small intestine (the ileum) where it joins the beginning of the colon. Crohn's disease may appear in "patches," affecting some areas of the gastrointestinal tract while leaving other sections completely untouched. (Crohn's and Colitis Foundation of America, 2014). Men and women can both be affected and the disease can occur at any age, but CD is more prevalent among women and in the young age population. Diet and stress may aggravate CD, but do not cause the disease. (Crohn's and Colitis UK, 2018; Crohn's and Colitis Foundation, 2020a). GlobalData epidemiologists ut......
$3995

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020" provides an overview of Functional (Non Ulcer) Dyspepsia Clinical trials scenario. This report provides top line data relating to the clinical trials on Functional (Non Ulcer) Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy